M 
Middle East Pharmaceutical Industries Company SJSC 4016.SR · SAR
Health Care · Tadawul · 🇸🇦 Saudi Arabia
62.05
-2.97%
Close of 9 Nov 2026, in SAR
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
At a glance
Figures in SAR, from our data supplier.
Revenue
SAR 460.5m
FY2019FY2025
Net income
SAR 97.0m
FY2019FY2025
Free cash flow
SAR 78.3m
FY2019FY2025
Shareholders' equity
SAR 416.2m
FY2019FY2025
Income statement
Fiscal years
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | |
|---|---|---|---|---|---|---|---|
| Revenue | SAR 460.5m | SAR 394.0m | SAR 338.4m | SAR 302.7m | SAR 287.2m | SAR 301.7m | SAR 232.1m |
| Gross profit | SAR 286.8m | SAR 243.4m | SAR 207.0m | SAR 177.7m | SAR 169.2m | SAR 171.8m | SAR 142.9m |
| Operating income | SAR 108.4m | SAR 91.0m | SAR 78.2m | SAR 70.3m | SAR 76.5m | SAR 81.1m | SAR 60.3m |
| Net income | SAR 97.0m | SAR 79.8m | SAR 65.8m | SAR 59.5m | SAR 66.3m | SAR 72.8m | SAR 54.1m |
| Diluted earnings per share | 4.85 | 3.50 | 3.29 | 2.97 | 3.31 | 3.64 | 2.70 |
Balance sheet
At each fiscal year end
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | |
|---|---|---|---|---|---|---|---|
| Total assets | SAR 599.5m | SAR 526.8m | SAR 444.9m | SAR 442.5m | SAR 416.9m | SAR 370.6m | SAR 283.3m |
| Cash and short-term investments | SAR 34.4m | SAR 22.6m | SAR 15.1m | SAR 23.8m | SAR 19.0m | SAR 15.9m | SAR 20.1m |
| Total liabilities | SAR 183.3m | SAR 158.6m | SAR 138.5m | SAR 162.2m | SAR 149.8m | SAR 118.2m | SAR 65.9m |
| Debt | SAR 63.7m | SAR 65.5m | SAR 62.0m | SAR 85.0m | SAR 87.0m | SAR 62.7m | SAR 12.6m |
| Shareholders' equity | SAR 416.2m | SAR 368.2m | SAR 306.4m | SAR 280.3m | SAR 267.1m | SAR 252.4m | SAR 217.4m |
| Shares outstanding | 20m | 23m | 20m | 20m | 20m | 20m | 20m |
Cash flow
Fiscal years
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | |
|---|---|---|---|---|---|---|---|
| Cash from operations | SAR 93.1m | SAR 35.3m | SAR 92.7m | SAR 64.6m | SAR 40.7m | SAR 44.4m | SAR 58.6m |
| Capital spending | −SAR 14.8m | −SAR 11.2m | −SAR 20.8m | −SAR 20.6m | −SAR 24.7m | −SAR 39.6m | −SAR 16.0m |
| Free cash flow | SAR 78.3m | SAR 24.1m | SAR 71.8m | SAR 44.0m | SAR 16.0m | SAR 4.8m | SAR 42.6m |
| Dividends paid | −SAR 47.0m | −SAR 15.0m | −SAR 36.0m | −SAR 36.3m | −SAR 37.2m | −SAR 36.3m | −SAR 24.0m |
Latest quarters
By quarter end
| Jun 2026 | Mar 2026 | Dec 2025 | Sept 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sept 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | SAR 136.5m | SAR 130.1m | SAR 137.5m | SAR 108.0m | SAR 117.7m | SAR 97.4m | SAR 136.0m | SAR 81.1m |
| Gross profit | SAR 85.5m | SAR 80.6m | SAR 90.5m | SAR 62.5m | SAR 73.6m | SAR 60.3m | SAR 86.5m | SAR 46.8m |
| Operating income | SAR 33.9m | SAR 31.2m | SAR 46.7m | SAR 12.4m | SAR 28.3m | SAR 22.3m | SAR 47.2m | SAR 6.9m |
| Net income | SAR 28.8m | SAR 26.9m | SAR 44.5m | SAR 8.3m | SAR 24.8m | SAR 19.4m | SAR 44.8m | SAR 3.9m |
| Diluted earnings per share | 0.82 | 0.77 | 2.23 | 0.41 | 1.24 | 0.97 | 1.96 | 0.17 |
| Cash from operations | SAR 22.0m | SAR 11.0m | SAR 19.0m | SAR 24.0m | SAR 30.0m | SAR 23.0m | SAR 22.0m | −SAR 29.0m |
| Capital spending | −SAR 17.0m | −SAR 16.0m | −SAR 1.0m | −SAR 8.0m | −SAR 12.0m | −SAR 7.0m | −SAR 2.0m | −SAR 1.0m |
| Free cash flow | SAR 5.0m | −SAR 5.0m | SAR 18.0m | SAR 16.0m | SAR 18.0m | SAR 16.0m | SAR 20.0m | −SAR 30.0m |
| Total assets | SAR 689.4m | SAR 626.5m | SAR 599.5m | SAR 565.6m | SAR 561.1m | SAR 548.3m | SAR 526.8m | SAR 494.0m |
| Cash and short-term investments | — | — | SAR 34.4m | SAR 19.4m | SAR 24.3m | SAR 33.9m | SAR 22.6m | SAR 13.8m |
| Debt | SAR 33.0m | SAR 27.8m | SAR 63.7m | SAR 62.4m | SAR 60.8m | SAR 62.4m | SAR 65.5m | SAR 73.6m |
| Shareholders' equity | SAR 445.5m | SAR 417.5m | SAR 416.2m | SAR 371.3m | SAR 385.2m | SAR 387.6m | SAR 368.2m | SAR 326.2m |
Financial ratios
Data as of 28 Oct 2026
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | |
|---|---|---|---|---|---|---|
| Gross margin | 62.3% | 61.8% | 61.2% | 58.7% | 58.9% | 56.9% |
| Operating margin | 23.5% | 23.1% | 22.9% | 23.3% | 25.6% | 26.7% |
| Net margin | 21.1% | 20.3% | 19.5% | 19.6% | 23.1% | 24.1% |
| Return on equity | 23.3% | 21.7% | 21.5% | 21.2% | 24.8% | 28.8% |
| Return on assets | 16.2% | 15.2% | 14.8% | 13.4% | 15.9% | 19.6% |
| Free cash flow yield | 9.1% | 3.4% | 9.5% | 7.2% | — | — |
| Revenue growth | 16.9% | 16.4% | 11.8% | 5.4% | -4.8% | 30.0% |
| Earnings growth | 21.5% | 21.3% | 10.7% | -10.3% | -9.0% | 34.7% |
| Current ratio | 3.13x | 2.65x | 2.45x | 2.22x | 2.29x | 2.66x |
| Debt to equity | 0.15x | 0.18x | 0.20x | 0.28x | 0.25x | 0.17x |
| Equity ratio | 69.4% | 69.9% | 68.9% | 63.3% | 64.1% | 68.1% |
| Interest coverage | 23.20x | 24.78x | 11.09x | 12.09x | 24.94x | 30.03x |
| Buybacks as a share of market value | 12.4% | -14.2% | 0.0% | — | — | — |
Growth per year
Compound annual rate
| 3 years | 5 years | 10 years | |
|---|---|---|---|
| Revenue | 15.0% | 8.8% | — |
| Operating income | 15.5% | 6.0% | — |
| Net income | 17.7% | 5.9% | — |
Average margins
Over each period
| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Gross margin | 62.0% | 61.2% | 60.3% | — |
| Operating margin | 23.3% | 23.3% | 24.3% | — |
| Net margin | 20.7% | 20.2% | 21.2% | — |
Valuation history
At each fiscal year end
| FY2025 | FY2024 | |
|---|---|---|
| Price to earnings | 13.1 | 19.9 |
| Price to sales | 2.8 | 4.0 |
Dividends and splits
Per share, in the currency the company pays
Paid for 2 years. Last went ex-dividend on 2 Sept 2026.
| FY2026 | FY2025 | FY2024 | |
|---|---|---|---|
| Paid in the year | 1.554 | 2.35 | 0.75 |
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.